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Abstract
Prostate cancer is the third-most common form of cancer in men in Romania. The Romanian unscreened population represents a good sample
to study common genetic risk variants. However, a comprehensive analysis has not been conducted yet. Here, we report our replication efforts
in a Romanian population of 979 cases and 1027 controls, for potential association of 34 literature-reported single nucleotide polymorphisms
(SNPs) with prostate cancer. We also examined whether any SNP was differentially associated with tumour grade or stage at diagnosis, with
disease aggressiveness, and with the levels of PSA (prostate specific antigen). In the allelic analysis, we replicated the previously reported risk
for 19 loci on 4q24, 6q25.3, 7p15.2, 8q24.21, 10q11.23, 10q26.13, 11p15.5, 11q13.2, 11q13.3. Statistically significant associations were repli-
cated for other six SNPs only with a particular disease phenotype: low-grade tumour and low PSA levels (rs1512268), high PSA levels
(rs401681 and rs11649743), less aggressive cancers (rs1465618, rs721048, rs17021918). The strongest association of our tested SNP’s with
PSA in controls was for rs2735839, with 29% increase for each copy of the major allele G, consistent with previous results. Our results suggest
that rs4962416, previously associated only with prostate cancer, is also associated with PSA levels, with 12% increase for each copy of the
minor allele C. The study enabled the replication of the effect for the majority of previously reported genetic variants in a set of clinically relevant
prostate cancers. This is the first replication study on these loci, known to associate with prostate cancer, in a Romanian population.
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Introduction
In Romania, prostate cancer is the third-most common form of can-
cer in males (after lung and colon cancers) with an age-standardized
incidence rate per 100,000 estimated to 37.9 in 2012. This incidence
rate is among the lowest in Europe and reflects the absence of a rou-
tinely PSA screening programme for prostate cancer. Instead, PSA
testing is recommended to the men having suggestive signs and
symptoms of prostate cancer and is followed by additional examina-
tions (DRE-digital rectal exam, ultrasound, biopsy). The vast majority
of incident cases have advanced disease at diagnosis carrying a poor
prognosis and inevitably resulting in death; the age-standardized mor-
tality rate is estimated to 16.3 per 100,000 in 2012 [1].
Prostate cancer does not have any strong environmental risk
factors but there is a great body of evidence that genetic factors may
contribute more than 60% of the population risk [2]. Genome wide
association (GWA) studies have yielded multiple common sequence
variants associated with prostate cancer risk. To date, more than 70
prostate cancer susceptibility loci have been identified, collectively
explaining about 30% of the familial risk for the disease [3].
The great majority of GWA studies of prostate cancer have been
performed in PSA-screened populations (Western Europe and USA)
and little is known about the risk estimates for populations from Cen-
tral and Eastern Europe. An example is Romania were screening for
prostate cancer is not common. The Romanian unscreened popula-
tion represents a good opportunity to study inherited risk genetic
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variants since the over diagnosis of indolent forms is not yet a major
problem. However, a comprehensive analysis of single nucleotide
polymorphisms (SNPs) known to be associated with prostate cancer
risk, based on GWA studies, has not been conducted in the Romanian
population. Here, we report our replication efforts in the Romanian
population for potential association of 34 literature-reported SNPs
with prostate cancer. We also examined whether any SNP was differ-
entially associated with tumour grade or stage at diagnosis, with
disease aggressiveness, and with the levels of PSA.
Material and methods
Cases and controls
Subjects included in this study were hospital patients admitted between
2008 and 2012 in two clinics in Bucharest (Urology Clinic ‘Th. Burghele’
and General Surgery Clinic ‘St. Mary’) for various urological and surgi-
cal conditions. We defined cases as men presenting for urinary tract
symptoms suggesting prostatic hyperplasia, with positive digital rectal
examination, abnormal PSA levels and first positive biopsy. Controls
were patients admitted for urological and surgical conditions, excluding
cancer. PSA level in plasma was measured for all subjects at hospital
admission but was not used as an exclusion criteria. Each eligible sub-
ject gave written informed consent prior to enrolment and accepted the
use of personal and clinical data and biological samples for genetic
research. Trained interviewers performed face-to-face interview, using
standardized questionnaires, to collect personal data (ethnicity, marital
status, education, height and weight), lifestyle data (occupation, smok-
ing, coffee and tea consumption) and medical history (personal and
familial). DNA was extracted from whole blood at deCODE Genetics lab-
oratories (Reykjavik, Iceland) for genotyping. The Bioethical Committee
of the Romanian College of Physicians approved the study.
We staged the cases using UICC – TNM staging system [4]. Men with
prostate cancer staged I-II cTNM were considered as low-stage and III-
IV cTNM as high-stage. Gleason score used in the study was based on
transrectal ultrasound guided needle core biopsy. The same pathologist
at The Urology Clinic ‘Th. Burghele’ reviewed all biopsy samples. Biop-
sies with Gleason score 1–7 were considered to be low-grade and biop-
sies with Gleason 8–10 were considered to be high-grade.
We defined aggressiveness according to pre-treatment risk stratifica-
tion used by Memorial Sloan-Kettering and Seattle groups [5]. For the
analysis, we grouped low and intermediate risk cases as less-aggressive
group.
Genotyping
We selected a panel of 34 SNPs found in large GWA studies [6–21].
The 34 SNPs were selected to represent the first prostate cancer risk
loci reported to reach genome-wide significance in GWA studies accord-
ing to the Catalog of Published Genome-Wide Association Studies
(http://www.genome.gov/26525384). Genomic DNA extraction from
peripheral blood was done using a semi-automated platform for high
quality, high throughput DNA extraction. The kits (Chemagic DNA
Blood10k kit), the equipment (Chemagic Magnetic Separation Module
MSM I) and the methods were from Chemagen (PerkinElmer chemagen
Technologie GmbH, Baesweiler, Germany). Single SNP genotyping of
the SNPs reported here was carried out by deCODE Genetics in Reyk-
javik, Iceland, applying the Centaurus (Epoch Biosciences, WA, USA)
platform [22]. The quality of each Centaurus SNP assay was evaluated
by genotyping each assay in the CEU and/or YRI HapMap samples and
comparing the results with the HapMap publicly released data. Assays
with >1.5% mismatch rate were not used.
Statistical analysis
We tested the Hardy–Weinberg equilibrium (HWE) for all 34 SNPs sepa-
rately among cases and controls through Chi square test with one grade
of freedom.
Allelic frequencies of SNPs in cases and controls were calculated
and tested through Fisher’s exact test. We defined the risk alleles as
variants that corresponds to the disease i.e. cancer odds ratio (OR)
greater than one. The association of each SNP with PSA levels was
tested using a linear regression model of the PSA values, on the natural
log scale, versus two independent variables: the number of minor alleles
(taken as reference) and age, respectively.
All reported P-values are uncorrected for multiple testing and are
based on a two-sided test. A level of P ≤ 0.05 was used to indicate sta-
tistical significance. Statistical analysis was performed using PLINK
v1.07 (Center for Human Genetic Research, Boston, Massachusetts,
United States and Broad Institute of Harvard & MIT, Cambridge, Mas-
sachusetts, United States; http://pngu.mgh.harvard.edu/purcell/plink/), R
v3.2.0 (R Foundation for Statistical Computing, Vienna, Austria; http://
www.R-project.org/) and Stata MP13 software (StataCorp LP, College
Station, Texas, United States).
Results
We genotyped 979 cases and 1027 controls, enrolled between May
2008 and Sept 2012. All recruited subjects were Romanian Cau-
casians. Table S1 presents the clinical characteristics of the cohort.
70.2% of cases had PSA levels >10 ng/ml reflecting an unscreened
population, with significant clinical disease at presentation (77% with
locally advanced tumours staged T3 and T4).
The genotyped SNPs did not deviate from HWE. MAFs (minor
allele frequencies) of the effect alleles in controls did not differ from
the original studies.
Single-locus tests of association (cases versus controls) were
conducted for each previously reported SNP. We calculated allelic
ORs and 95% confidence intervals (CIs) and we compared the results
with reference ORs from original GWAS (Table 1). Nineteen SNPs of
34 SNPs tested were nominally significantly (P < 0.05) associated
with the disease. The association was in the same direction as in the
reference studies with the magnitude of risk similar or greater than
previously reported for variants on 4q24, 6q25.3, 7p15.2, 8q24.21,
11p15.5, 11q13.2. Five other SNPs on 2p21, 2p15, 4q22.3, 8p21.2,
17q12 showed direction of effect consistent with the original reports,
but non-significant. For the variants tested on 2q31.1, 3p12.1,
3q21.3, 7q21.3, 17p12, 17q24.3, 19q13.2 and 22q13.1, we could not
reproduce the effect on risk for any of the disease phenotypes investi-
gated. Based on P-values, the strongest association observed was for
rs445114 on 8q24.21 (P = 0.000013). The highest OR was 1.58 (for
rs16901979 on 8q24.21).
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Secondly, we tested if these 34 SNPs are differentially associated
with clinico-pathological characteristics of the disease at diagnosis:
clinical stage (cTNM), Gleason score on first biopsy, pre-operatory
PSA levels and aggressiveness.
High stage cTNM did not modify the risk estimates. The associa-
tion with the risk alleles at 6q25.3 (rs9364554) and 11q13.3
(rs10896450) became stronger for cases staged cTNM I and II
(Table S2). Rs2735839 (on 19q13.33) was strongly associated only
with the low stage cTNM (OR = 1.69, CI = 1.11–2.63, P = 0.009).
In the analysis of the pathological features of the tumours based
on Gleason grade on biopsy, we found a significant increased risk for
high grade tumours (Gleason 8–10) associated with the variants on
8q24.21 (Table S2).
The ORs for prostate cancer did not differ significantly by periop-
erative PSA levels (Table S3). However, the risk associated with
rs401681 on 5p15.33 and rs11649743 on 17q12 became significant
stronger (OR = 1.19, CI = 1.02–1.39, P = 0.027 and OR = 1.23,
CI = 1.00–1.52, P = 0.047 respectively) for high PSA values.
A quantitative regression association of the PSA values with the
34 SNP’s was performed in cases, controls, and in the mixed group
(Table S4). However, given the correlation (or confounding) of the
high PSA levels with the disease, the most relevant analysis is the
one for the population controls only. This analysis detected four SNPs
with low p-values: rs2735839 (19q13.33, P = 0.0004), rs2736098
(5p15.33, P = 0.023), rs10993994 (10q11.23, P = 0.010), and
rs4962416 (10q26.13, P = 0.018). The first three SNPs were previ-
ously reported in association with high PSA levels in other popula-
tions [23] and therefore can be considered only indirectly associated
with prostate cancer. Gudmundsson et al. also reported another SNP
associated with PSA, rs10788160 (10q26.12, close to FGFR2 gene),
whereas our fourth SNP (rs4962416) is located 3.66 Mb further,
within the gene CTBP2, and not in LD with rs10788160. Rs4962416
has been previously associated with prostate cancer, but not with the
PSA levels in non-cancer patients. The increase of PSA levels corre-
sponds to 12% for each copy of the minor allele C (or 0.113 on the
log scale). The strongest association with PSA was for rs2735839,
which is located near the KLK3 gene that encodes PSA, with 29%
increase for each copy of the major allele G, consistent with previous
results reported by Gudmundsson et al.
When cases were divided into categories of disease severity by a
combination of high-risk clinical variables (cTNM, Gleason score,
PSA levels at diagnosis), three SNPs showed significant association
but only with less aggressive disease (rs1465618, rs721048,
rs17021918). The risk at 6q25.3, 11q13.3 and 19q13.33 (rs2735839)
was significantly higher for the cases having less severe disease
(Table S4).
Markers on 6q25.3 (rs9364554) and on 11q13.3 (rs10896450)
associated with all the phenotypes tested with ORs particularly high
for the less aggressive variants.
Discussion
In recent years, a large amount of information on prostate cancer risk
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ples. However, less is known about whether these associations can
be consistently replicated in Eastern European populations [24]. A
recent study reported on the associations of prostate cancer risk with
two loci on chromosome 17q12 (rs3760511 and rs7501939) in the
Serbian population [25]. Another large study on Polish men reported
on the positive associations with prostate cancer for 5 of 11 studied
SNPs [26].
To our best knowledge, this is the first study set out to examine
34 SNPs previously identified for association with prostate cancer in
a Romanian hospital-based case–control series of unscreened men
and to evaluate if there is any variation in risk by diseases severity at
diagnosis.
We found evidence of similar or higher association with prostate
cancer risk for 24 SNPs investigated. Six other literature-reported
variants reached nominal significance only for particular forms of the
disease. The previously reported associations with PrCa for loci on
2q31.1, 3p12.1, 3q21.3, 7q21.3, 17p12, 17q24.3, 19q13.2, 22q13.1
were not replicated in our study. Our failure to replicate all markers is
not unexpected as previous studies report only 25–60% successful
replication of prostate cancer association SNPs [27]. This failure can
possibly be linked to the sample size leading to insufficient statistical
power, but more likely to the much weaker, if not even inexistent,
effect in the Romanian population, and hence to a higher, population
dependent, cancer heterogeneity [28].
In our study population, the strongest nominal associations were
for variants on 8q24; for any SNPs that were significant in the allelic
analysis, the OR was consistently more extreme for high-grade
prostate cancer than reported in discovery studies [29]. However, the
results for the aggressive phenotype were similar to the results
of all prostate cancer cases indicating that SNPs on 8q24 do not offer
substantial discrimination between these two distinguishable
phenotypes.
We observed a strong association with less aggressive disease
for rs1465618 on 2p21 (OR = 1.37; CI = 1.06–1.76, P = 0.016)
and rs721048 on 2p15 (OR = 1.43; CI = 1.05–1.93, P = 0.019)
which is in contrast with other previous reports [6, 30]. The risk
allele at rs17021918 was associated only with low aggressiveness;
similar findings were reported by Shui [31]. For the SNPs associ-
ated with PSA levels in controls, we observed a stronger associa-
tion with low-grade tumours (rs10993994 and rs4962416 on 10q,
rs2735839 on 19q13.33) or high-grade tumours (rs2736098 on
5p15.33).
Previous reports have shown genomic variants at 10q to be asso-
ciated with both PSA levels in healthy controls and with cancer risk in
average and high-risk Caucasian men [32–34]. The role of
rs10993994 in the discrimination of aggressive versus non-aggres-
sive cancers is controversial since the chromosome 10q11 prostate
cancer risk locus is associated with decreased levels of MSMB and
increased levels of NCOA4 RNA expression; both genes have been
suggested to mediate prostate tumourigenesis (initiation and pro-
gression) [35].
Our results for rs2735839, rs2736098, and rs10993994 show
a clear tendency for the alleles associated with prostate cancer
risk to be also associated with PSA levels in controls which is in
line with results reported by Gudmundsson et al. [23]. In addition
we also observed a similar effect for rs4962416, within the gene
CTBP2, suggesting that this gene may also be primarily linked to
PSA, and not directly to cancer. Since the obtained P-value is not
convincingly low, considering multiple testing corrections, this
association needs further confirmation. The purpose of this study
was a replication of previously known SNPs, and therefore the
P-values were not corrected for multiple testing. On the other
hand, a limitation is that the sample size was smaller than in the
previous studies, and our risk estimates have larger confidence
intervals.
Our present cohort of about 2000 individuals has a reasonable
power to detect common variants with allelic relative risk of about 1.2
or larger. To evaluate the possible effect of the unconfirmed SNPs or
to detect novel risk variants in the Romanian population further larger
samples are needed.
Conclusions
Our study provides evidence that the majority of previously validated
prostate cancer SNPs associates with risk in the Romanian non-
screened population, having relevant clinical disease, and can be con-
sidered for inclusion in future risk models of potential clinical utility.
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